|
[1]
|
Mensah, G.A., Fuster, V., Murray, C.J.L., Roth, G.A., Mensah, G.A., Abate, Y.H., et al. (2023) Global Burden of Cardiovascular Diseases and Risks, 1990-2022. Journal of the American College of Cardiology, 82, 2350-2473. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Mensah, G.A., Fuster, V. and Roth, G.A. (2023) A Heart-Healthy and Stroke-Free World. Journal of the American College of Cardiology, 82, 2343-2349. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Sampson, U.K., Fazio, S. and Linton, M.F. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports, 14, 1-10. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Averna, M., Stroes, E., Ogura, M., Postadzhiyan, A., Cercek, M., Calabrò, P., et al. (2017) How to Assess and Manage Cardiovascular Risk Associated with Lipid Alterations beyond LDL. Atherosclerosis Supplements, 26, 16-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wang, L., Zhang, Q., Wu, Z. and Huang, X. (2024) A Significant Presence in Atherosclerotic Cardiovascular Disease: Remnant Cholesterol: A Review. Medicine, 103, e38754. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., et al. (2023) Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk. International Journal of Molecular Sciences, 24, Article 4268. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Martin, S.S., Blaha, M.J., Elshazly, M.B., Toth, P.P., Kwiterovich, P.O., Blumenthal, R.S., et al. (2013) Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile. JAMA, 310, 2061-2068. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Lütjohann, D., Klör, H. and Stellaard, F. (2023) Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations. Nutrients, 15, Article 2202. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Chen, J., Kuang, J., Tang, X., Mao, L., Guo, X., Luo, Q., et al. (2020) Comparison of Calculated Remnant Lipoprotein Cholesterol Levels with Levels Directly Measured by Nuclear Magnetic Resonance. Lipids in Health and Disease, 19, Article No. 132. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Varbo, A. and Nordestgaard, B.G. (2021) Directly Measured vs. Calculated Remnant Cholesterol Identifies Additional Overlooked Individuals in the General Population at Higher Risk of Myocardial Infarction. European Heart Journal, 42, 4833-4843. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Ginsberg, H.N., Packard, C.J., Chapman, M.J., Borén, J., Aguilar-Salinas, C.A., Averna, M., et al. (2021) Triglyceride-rich Lipoproteins and Their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therapeutic Strategies—A Consensus Statement from the European Atherosclerosis Society. European Heart Journal, 42, 4791-4806. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Borén, J., Chapman, M.J., Krauss, R.M., Packard, C.J., Bentzon, J.F., Binder, C.J., et al. (2020) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 41, 2313-2330. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Castañer, O., Pintó, X., Subirana, I., Amor, A.J., Ros, E., Hernáez, Á., et al. (2020) Remnant Cholesterol, Not LDL Cholesterol, Is Associated with Incident Cardiovascular Disease. Journal of the American College of Cardiology, 76, 2712-2724. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Quispe, R., Martin, S.S., Michos, E.D., Lamba, I., Blumenthal, R.S., Saeed, A., et al. (2021) Remnant Cholesterol Predicts Cardiovascular Disease Beyond LDL and APOB: A Primary Prevention Study. European Heart Journal, 42, 4324-4332. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lee, S.J., Kim, S.E., Go, T.H., Kang, D.R., Jeon, H.S., Kim, Y.I., Cho, D.H., Park, Y.J., Lee, J.H., Lee, J.W., Youn, Y.J., Kim, S.H., Kim, J.Y. and Ahn, S.G. (2023) Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Incident Cardiovascular Disease among Koreans: A National Population-Based Study. European Journal of Preventive Cardiology, 30, 1142-1150.
|
|
[16]
|
Wadström, B.N., Wulff, A.B., Pedersen, K.M., Jensen, G.B. and Nordestgaard, B.G. (2021) Elevated Remnant Cholesterol Increases the Risk of Peripheral Artery Disease, Myocardial Infarction, and Ischaemic Stroke: A Cohort-Based Study. European Heart Journal, 43, 3258-3269. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Feng, Q., Li, H., Zhang, R., Sun, L., Zhang, S., Chen, Y., et al. (2024) Elevated Remnant Cholesterol Is a Risk Factor for Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 33, Article ID: 107773. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Zhang, P., Zhang, Z., Li, D., Han, R., Li, H., Ma, J., et al. (2023) Association of Remnant Cholesterol with Intracranial Atherosclerosis in Community-Based Population: The ARIC Study. Journal of Stroke and Cerebrovascular Diseases, 32, Article ID: 107293. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Huh, J.H., Han, K., Cho, Y.K., Roh, E., Kang, J.G., Lee, S.J., et al. (2022) Remnant Cholesterol and the Risk of Cardiovascular Disease in Type 2 Diabetes: A Nationwide Longitudinal Cohort Study. Cardiovascular Diabetology, 21, Article No. 228. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Fu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., et al. (2022) Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients with Type 2 Diabetes: Findings from the ACCORD Cohort. Diabetes Care, 45, 2136-2143. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Doi, T., Langsted, A. and Nordestgaard, B.G. (2023) Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans. Journal of Atherosclerosis and Thrombosis, 30, 1525-1546. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188.
|
|
[23]
|
Mohamed, F., Mansfield, B.S. and Raal, F.J. (2022) ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Current Atherosclerosis Reports, 24, 959-967. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Ballantyne, C.M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R.S., Chang, T., et al. (2024) Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine, 391, 899-912. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Rosenson, R.S., Gaudet, D., Hegele, R.A., Ballantyne, C.M., Nicholls, S.J., Lucas, K.J., et al. (2024) Zodasiran, an Rnai Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine, 391, 913-925. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Guo, D., Gao, J., Wang, X., Chen, Z., Gao, Q., Chen, Y., et al. (2024) Remnant Cholesterol and Risk of Incident Hypertension: A Population-Based Prospective Cohort Study. Hypertension Research, 47, 1157-1166. [Google Scholar] [CrossRef] [PubMed]
|